Results 261 to 270 of about 75,748 (340)

Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 1, January 2026.
Integrated framework for tirzepatide in HFpEF management. Through metabolic, haemodynamic, structural and anti‐inflammatory pathways, tirzepatide modifies the disease trajectory of HFpEF, leading to improvements in symptoms, functional capacity and reduction in HF events.
Hamza A. Abdul‐Hafez, Ameer Awashra, Sosana Bdir, Sarah Saife, Qasem Salah, Mohammed Barbarawi, Thabet Swaileh, Ahmed Emara, Mohamed S. Elgendy, Abdalhakim Shubietah   +9 more
wiley   +1 more source

The Role of NT-proBNP in the Diagnosis of Peripartum Cardiomyopathy with Multiple Left Ventricular Thrombus: A Case Report

Yashinta Octavian Gita Setyanda, Rismawati Yaswir   +1 more
openalex   +2 more sources

The predictive value of NT-proBNP and hs-TnT for risk of death in cardiac surgical patients

, 2018
Jon Brynildsen, Liisa Petäjä, Ville Pettilä, Ståle Nygård, Suvi T. Vaara, Rita Linko, Marjatta Okkonen, Tor‐Arne Hagve, Leena Soininen, Raili Suojaranta-Ylinen, Magnus Nakrem Lyngbakken, Torbjørn Omland, Helge Røsjø   +12 more
openalex   +2 more sources

Safety and Tolerability of Withania somnifera Root Extract in Healthy Male Participants: A Pilot Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial

Food Science &Nutrition, Volume 14, Issue 1, January 2026.
Withania somnifera (WS) or Ashwagandha is valued for its anti‐inflammatory, antioxidant, adaptogenic, and memory‐enhancing properties. This randomized, placebo‐controlled and double‐blind study assessed the safety of standardized WS root extract in healthy adult participants over 180 days. The study concluded that WS root extract (200 mg capsules twice
Narendra Vaidya, Ramshyam Agarwal, Pankaj Kshirsagar, Gayatri Ganu, Dheeraj Nagore, Anirudh Mehta, Ashit Vora, Sujit Nair   +7 more
wiley   +1 more source

The Interplay of Prolactin with Inflammatory Nutritional Markers and NT-proBNP in Chronic Kidney Disease. [PDF]

Int J Mol Sci
Rusu CC, Moldovan D, Potra A, Tirinescu D, Ticala M, Maslyennikov Y, Barar A, Urs A, Bondor CI, Valea A, Kacso I.   +10 more
europepmc   +1 more source

Metabolic Profiling of the EmDia Cohort by LC‐MS Reveals Empagliflozin‐Intake Associated Regulation of 1,5‐anhydroglucitol and Urate

PROTEOMICS, Volume 26, Issue 1, Page 44-56, January 2026.
ABSTRACT The EmDia trial, designed to study the effects of the sodium glucose cotransporter‐2 (SGLT2) inhibitor empagliflozin on cardiovascular comorbidities in type 2 diabetes mellitus (T2DM) patients, has been investigated for short‐term metabolic alterations by a limited set of clinical assays. To expand on this data, we report on the development of
Fabian Schmitt, Vincent ten Cate, Zlatka Fischer, Mathias Hagen, Barbara A. Steigenberger, Stefan Tenzer, Philipp S. Wild, Thierry Schmidlin   +7 more
wiley   +1 more source

Cardiac Overload and Heart Failure Risk by NT-proBNP Levels in Older Adults with COPD Eligible for Single-Inhaler Triple Therapy: A Multicenter Longitudinal Study. [PDF]

J Clin Med
Sarzani R, Spannella F, Laureti G, Giordano P, Giulietti F, Gezzi A, Mari PV, Coppola A, Galeazzi R, Rosati Y, Kamberi E, Stronati A, Resedi A, Landolfo M.   +13 more
europepmc   +1 more source

Proteomic Biomarkers Are Linked to QTc Interval in Patients With Chronic Heart Failure

PROTEOMICS – Clinical Applications, Volume 20, Issue 1, January 2026.
ABSTRACT Objective This study investigates the link between circulating proteins and rate‐corrected QT (QTc) interval in patients with heart failure with reduced ejection fraction (HFrEF) and their association with cardiovascular outcomes. Methods and Results We analyzed 197 HFrEF patients from the prospective Serial Biomarker Measurements and New ...
Mylène Barry‐Loncq de Jong, Teun B. Petersen, Sabrina Abou Kamar, Navin Suthahar, Nick van Boven, K. Martijn Akkerhuis, Peter J. van der Spek, Peter D. Katsikis, Rudolf A. de Boer, Victor A. W. M. Umans, Eric Boersma, Folkert W. Asselbergs, Jasper J. Brugts, Sing‐Chien Yap, Isabella Kardys   +14 more
wiley   +1 more source

The Impact of Volume Removal by Hemodialysis on Elevated NT-proBNP Levels in Patients With Hypervolemia. [PDF]

Cureus
Tinawi M, Bastani B.
europepmc   +1 more source

Prognostic value of pathogenetic therapy-induced changes in NT-proBNP in patients with chronic heart failure

, 2012
E. M. Mezhonov, S V Shalaev
openalex   +1 more source